HCT shows curative potential in high-risk T-cell lymphoma

Allogeneic hematopoietic transplantation yielded durable disease control for patients with relapsed or refractory or otherwise high-risk T-cell lymphoma, according to a presentation at ASH Annual Meeting and Exposition.

The study, which is the largest retrospective analysis of HCT in T-cell lymphoma, included 500 patients across 12 centers with a variety of T-cell lymphomas, Stefan K. Barta, MD, MS, MRCP, director of the T-Cell Lymphoma Program at Penn Medicine, told Healio in a video interview.

The treatment-related mortality rate was 11.2%, which Barta said is “pretty amazing.” The 2-year OS and PFS rate following allogeneic hematopoietic transplantation were 59.1% and 45.8%, and the 5-year OS and PFS rate were 50.8% (95%CI, 46.1-55.3%) and 39.4%, according to the abstract.

“Over the last 2 decades, we’ve been much better in A, typing our patients and finding better donors and B, managing infections and graph host disease so supportive care has improved,” Barta said. “This [study] underpins the allogenic transplant as a very reasonable option for patients specifically who achieved a complete response to salvage therapy. It provides us great information and numbers to discuss this option with our patients – in that respect, it’s a very important study.”

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Back to Healio

Discoveries in Lymphoma